Verrica Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview

Verrica Pharmaceuticals

16/02/2024 14:04

* Verrica Pharmaceuticals Inc  VRCA.OQ   VRCA.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 19 (estimated) for the period ending December 31 2023
    * The West Chester Pennsylvania-based  company is expected
to
report a 1,242.3% increase in revenue to $912.75 thousand from
$68 thousand a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Verrica Pharmaceuticals
Inc is
for a loss of 53 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Verrica
Pharmaceuticals Inc is $13.00​, above​ its last closing price
of $5.56. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.35       -0.36      -0.54     Missed  -49.5
 Jun. 30 2023  -0.22       -0.21      -0.24     Missed  -14.2
 Mar. 31 2023  -0.18       -0.19      -0.15     Beat    21.1​
 Dec. 31 2022  -0.19       -0.19      -0.14     Beat    27.3
 ​​Sep.        -0.17       -0.11      0.03      Beat    126.4
 30 2022                                                
 Jun. 30 2022  -0.28       -0.32      -0.37     Missed  -15.3​
 Mar. 31 2022  -0.45       -0.47      -0.31     Beat    34.3
 Dec. 31 2021  -0.48       -0.50      -0.35     Beat    29.6
 This summary was machine generated February 16 at 14:04 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)